The long-awaited and overdue half-point cut in the federal funds rate was the impetus for the SPDR Biotech ETF to finally break above the 102-103 level. Meanwhile, Bicycle Therapeutics Plc. had a strong ESMO following promising new data
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safety over competitors. The analyst projects ~$2 billion in peak sales by 2033 and sees opportunities beyond metastatic urothelial cancer.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today’s session.
